Resistência genotípica em pacientes com falha virológica os antirretrovirais da classe da integrase
Santos, Juciane Soares.
São Paulo; SES/SP; 2020. 43 p. ilus.
Monografia Português | SES-SP, LILACS, SES-SP, SES SP - Especializações, SES-SP | ID: biblio-1128461
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
Specific mutations in the HIV-1 G-tract of the 3'-polypurine tract cause resistance to integrase strand transfer inhibitors.
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
Life-long Antiretroviral Therapy: Playing the Long Game.
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir.
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary.
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.